Trial Profile
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Palovarotene in Subjects With Multiple Osteochondromas
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 04 Aug 2022
Price :
$35
*
At a glance
- Drugs Palovarotene (Primary)
- Indications Bone disorders
- Focus Therapeutic Use
- Acronyms MO-Ped
- Sponsors Clementia Pharmaceuticals
- 28 Nov 2020 This trial has been completed in France according to European Clinical Trials Database record.
- 23 Oct 2020 Planned End Date changed from 1 Sep 2020 to 10 Nov 2020.
- 29 Apr 2020 Planned End Date changed from 1 Feb 2021 to 1 Sep 2020.